Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymalfasin dosing schedule study after adjuvant chemotherapy for stage IIB lung adenocarcinoma
ChiCTR2000030244Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Dec 2018
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of thymosin alpha 1 in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Peripheral blood T lymphocyte subsets count. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000030244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030244.